* If you want to update the article please login/register
In patients with gynecological cancers, the recommended phase II dose and safety profile of adavosertib is determined. In combination with standard radiotherapy and concurrent cisplatin, we were able to determine the acute and late toxicity of AZD1775 in combination with standard radiotherapy and concurrent cisplatin. Patients receive adavosertib orally on days 1, 3, 5, and 5 or 3 times a day, with cisplatin intravenously over 1 hour on day 1 or 3.
Source link: https://clinicaltrials.gov/ct2/show/NCT03345784
Radiation oncologists can more precisely and precisely target radiation to areas of risk while still sparing healthy tissue as a result of advancement. Radiation oncologists have increased the use of hypofractionated treatment protocols, which has enabled radiation oncologists to successfully quantify and precisely deliver radiation to target volumes while still retaining safe doses to the relevant organs-at-risk. The treatment should be safe and well tolerated with minimal effect on patient quality of life through precision delivery and careful dosimetry.
Source link: https://clinicaltrials.gov/ct2/show/NCT04866394
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions